Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 55-63 , March 2009

Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote

  • Raisuddin Ali, MPharm

      Affiliations

    • Faculty of Pharmacy, Department of Pharmaceutics, Hamdard University, New Delhi, India
    • ,
  • Gaurav K. Jain, MPharm

      Affiliations

    • Faculty of Pharmacy, Department of Pharmaceutics, Hamdard University, New Delhi, India
    • ,
  • Zeenat Iqbal, PhD

      Affiliations

    • Faculty of Pharmacy, Department of Pharmaceutics, Hamdard University, New Delhi, India
    • ,
  • Sushma Talegaonkar, PhD

      Affiliations

    • Faculty of Pharmacy, Department of Pharmaceutics, Hamdard University, New Delhi, India
    • ,
  • Pragati Pandit, PhD

      Affiliations

    • Cipla Ltd., Mumbai, India
    • ,
  • Sunita Sule, BPharm

      Affiliations

    • Cipla Ltd., Mumbai, India
    • ,
  • Geena Malhotra, BPharm

      Affiliations

    • Cipla Ltd., Mumbai, India
    • ,
  • Roop K. Khar, PhD

      Affiliations

    • Faculty of Pharmacy, Department of Pharmaceutics, Hamdard University, New Delhi, India
    • ,
  • Aseem Bhatnagar, MD

      Affiliations

    • Division of Nuclear Medicine, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India
    • Corresponding Author InformationCorresponding author.
    • ,
  • Farhan J. Ahmad, PhD

      Affiliations

    • Faculty of Pharmacy, Department of Pharmaceutics, Hamdard University, New Delhi, India

Received 17 July 2007 ,Accepted 11 July 2008.

References 

  1. Chapman WP, Rowlands P, Jones CM. Antispasmodic drugs: evaluation of their effects on the motor activity of the upper portion of the small intestine in man. JAMA. 1950;143:627–630
  2. Kehe CR, Lasseter KC, Miller NC, Wick KA, Shamblen EC, Ekholm BP. Comparative absorption of atropine from a metered dose inhaler and an intramuscular injection. Ther Drug Monitor. 1992;14:132–134
  3. Callahan JC, Cleary GW, Elefant M. Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm. 1982;8:355–369
  4. Xu A, Havel J, Linderholm K, Hulse J. Development and validation of an LC/MS/MS method for the determination of l-hyoscyamine in human plasma. J Pharm Biomed Anal. 1995;14:33–42
  5. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary delivery. Pharm Res. 2007;24:411–437
  6. Dollery C. In: Therapeutic drugs. 2nd ed.. New York: Churchill Livingstone; 1999;p. A240–A245
  7. Podczeck F. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. Int J Pharm. 1998;160:119
  8. Zeng XM, Martin GP, Tee S, Ghoush AA, Marriott C. Effect of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int J Pharm. 1999;182:133
  9. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv. 2001;68:27–42
  10. Dateand AA, Patravale VB. Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interf. 2004;9:222–235
  11. Midoux N, Hosek P, Pailleres L, Authelin JR. Micronization of pharmaceutical substances in a spiral jet mill. Powder Technol. 1999;104:113–120
  12. Liversidge EM, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18:113–120
  13. Krause KP, Muller RH. Production and characterization of highly concentrated nanosuspensions by high pressure homogenization. Int J Pharm. 2001;214:21–24
  14. Reverchon E. Supercritical antisolvent precipitation of micro- and nanoparticles. J Supercrit Fluid. 1999;15:1–21
  15. Chattopadhyay P, Gupta RB. Production of antibiotic nanoparticles using supercritical CO2 as antisolvent with enhanced mass transfer. Ind Eng Chem Res. 2001;40:3530–3539
  16. Charoenchaitrakool M, Dehghani F, Foster NR. Micronization by rapid expansion of supercritical solutions to enhance the dissolution rates of poorly water-soluble pharmaceuticals. Ind Eng Chem Res. 2000;39:4794–4802
  17. Pathak P, Meziani MJ, Desai T, Sun Y. Nanosizing drug particles in supercritical fluid processing. J Am Chem Soc. 2004;126:10842–10843
  18. Rasenack N, Steckel H, Muller BW. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci. 2003;92:35–44
  19. Mathiowitz E, Thanos C, Liu Z. Methods for micronization of hydrophobic drugs. United States Patent US6824791. August 26, 2004.
  20. Rasenack N, Steckel H, Muller BW. Preparation of microcrystals by in situ micronization. Powder Technol. 2004;143-144:291–296
  21. Brittain HG, Fiese EF. Effects of pharmaceutical processing on drug polymorphs and solvates. In:  Brittain HG editors. Polymorphism in pharmaceutical solids. New York: Marcel Dekker; 1999;p. 332–358
  22. Tong HHY, Chow AHL. Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing. Chem Inform. 2007;21:27–40

 No conflict of interest was reported by the authors of this paper.

PII: S1549-9634(08)00094-4

doi: 10.1016/j.nano.2008.07.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 55-63 , March 2009

Article Tools

* Image Usage & Resolution